Sanofi Ventures

Founded 1994

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Average round size
info
The average size of a deal this fund participated in
$35M
Portfolio companies 40
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 15
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

$17M10 May 2021 -

$100M07 Apr 2021
-

Medisafe

Fitness
Health Care
Medical
mHealth
Mobile Apps
$30M25 Feb 2021 United States, Boston

DiCE Molecules

Biotechnology
Medical
Medical Device
$80M08 Jan 2021 United States, " United States"}

Abcuro

Biotechnology
Health Care
Medical
Therapeutics
$42M07 Jan 2021 United States, Newton

Q32 Bio

Biotechnology
Health Care
Medical
Therapeutics
$60M29 Oct 2020 United States, Cambridge

Lava Therapeutics

Biotechnology
Life Science
Medical
Medical Device
$83M17 Sep 2020 Netherlands, Utrecht

Escient Pharmaceuticals

Biotechnology
Pharmaceutical
$77M14 Sep 2020 United States, San Diego

Science 37

Biotechnology
Clinical Trials
Health Care
Mobile
$40M20 Aug 2020 United States, Los Angeles
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

– ROME Therapeutics announced the completion of a $77m Series B financing round.
– The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
– ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
– ROME has identified multiple repeatome-derived targets and created an internal data science platform, called repeatomics, to analyze vast quantities of data available through the repeatome.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sanofi Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: